Cargando…

A systematic review and network meta‐analysis of immunotherapy and targeted therapy for advanced melanoma

Immune and BRAF‐targeted therapies have changed the therapeutic scenario of advanced melanoma, turning the clinical decision‐making a challenging task. This Bayesian network meta‐analysis assesses the role of immunotherapies and targeted therapies for advanced melanoma. We retrieved randomized contr...

Descripción completa

Detalles Bibliográficos
Autores principales:	da Silveira Nogueira Lima, Joao Paulo, Georgieva, Mina, Haaland, Benjamin, de Lima Lopes, Gilberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5463084/ https://www.ncbi.nlm.nih.gov/pubmed/28463413 http://dx.doi.org/10.1002/cam4.1001

Ejemplares similares

Meta‐analysis of first‐line therapies with maintenance regimens for advanced non‐small‐cell lung cancer (NSCLC) in molecularly and clinically selected populations
por: Tan, Pui San, et al.
Publicado: (2017)

Comparative Efficacy and Safety of Programmed Death-1 Pathway Inhibitors in Advanced Gastroesophageal Cancers: A Systematic Review and Network Meta-Analysis of Phase III Clinical Trials
por: da Silva, Laercio Lopes, et al.
Publicado: (2021)

Decreased survival in patients treated by chemotherapy after targeted therapy compared to immunotherapy in metastatic melanoma
por: Mangin, Marie‐Alix, et al.
Publicado: (2021)

Real world outcomes of combination and timing of immunotherapy with radiotherapy for melanoma with brain metastases
por: Moyers, Justin T., et al.
Publicado: (2021)

Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma
por: Krebs, Franziska K., et al.
Publicado: (2021)

Effect of targeted therapy and immunotherapy on advanced nonsmall‐cell lung cancer outcomes in the real world
por: Shokoohi, Aria, et al.
Publicado: (2021)

Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma
por: Rosner, Samuel, et al.
Publicado: (2018)

Targeted first-line therapies for advanced colorectal cancer: a Bayesian meta-analysis
por: Ridouane, Yassine, et al.
Publicado: (2017)

Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies
por: Adegoke, Nurudeen A, et al.
Publicado: (2023)

Role of Sarcopenia in Advanced Malignant Cutaneous Melanoma Treated with Immunotherapy: A Meta-Analysis
por: Surov, Alexey, et al.
Publicado: (2022)

Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy
por: Bhave, Prachi, et al.
Publicado: (2023)

Targeted Therapy and Immunotherapy for Melanoma in Japan
por: Namikawa, Kenjiro, et al.
Publicado: (2019)

Update on combined immunotherapy for the treatment of advanced renal cell carcinoma
por: Gebrael, Georges, et al.
Publicado: (2023)

Treatment of melanoma of unknown primary in the era of immunotherapy and targeted therapy: A Dutch population‐based study
por: Verver, D, et al.
Publicado: (2019)

Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma
por: Pokorny, Rebecca, et al.
Publicado: (2021)

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations
por: Haaland, Benjamin, et al.
Publicado: (2014)

Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non‐small cell lung cancer
por: Nishioka, Naoya, et al.
Publicado: (2020)

Three models that predict the efficacy of immunotherapy in Chinese patients with advanced non‐small cell lung cancer
por: Zhao, Qian, et al.
Publicado: (2021)

Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study
por: Rutkowski, Piotr, et al.
Publicado: (2020)

Patient reported symptoms associated with quality of life during chemo‐ or immunotherapy for bladder cancer patients with advanced disease
por: Taarnhøj, Gry A., et al.
Publicado: (2020)

Curative-Intent Surgery for Pancreatic Tumors: A Review of Procedures From the Brazilian National Health System
por: dos Santos, Lucas V., et al.
Publicado: (2016)

Clinical outcomes of BRAF plus MEK inhibition in melanoma: A meta‐analysis and systematic review
por: Yu, Qingliang, et al.
Publicado: (2019)

Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations
por: Helgadottir, Hildur, et al.
Publicado: (2020)

Angiopoietin-2–Dependent Spatial Vascular Destabilization Promotes T-cell Exclusion and Limits Immunotherapy in Melanoma
por: Park, Ha-Ram, et al.
Publicado: (2023)

Real‐world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study
por: Middleton, Mark R., et al.
Publicado: (2016)

Survival outcomes in an older US population with advanced melanoma and central nervous system metastases: SEER‐Medicare analysis
por: Sadetsky, Natalia, et al.
Publicado: (2020)

Immunotherapies for hepatocellular carcinoma
por: Liu, Justin K. H., et al.
Publicado: (2021)

Advances in immunotherapy for cervical cancer
por: Grau-Bejar, Juan Francisco, et al.
Publicado: (2023)

Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases
por: Niessner, Heike, et al.
Publicado: (2013)

Neoantigen Targetability in Progressive Advanced Melanoma
por: van den Bulk, Jitske, et al.
Publicado: (2023)

Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy
por: Pinter, Matthias, et al.
Publicado: (2017)

Advances in immunotherapy for melanoma
por: Redman, Jason M., et al.
Publicado: (2016)

Outcomes of stage IV melanoma in the era of immunotherapy: a National Cancer Database (NCDB) analysis from 2014 to 2016
por: Sussman, Tamara A, et al.
Publicado: (2022)

Nanoparticle delivery of miR-21-3p sensitizes melanoma to anti-PD-1 immunotherapy by promoting ferroptosis
por: Guo, Weinan, et al.
Publicado: (2022)

Novel cancer therapies for advanced cutaneous melanoma: The added value of radiomics in the decision making process–A systematic review
por: Guerrisi, Antonino, et al.
Publicado: (2020)

Toxicity and efficacy of Gamma Knife radiosurgery for brain metastases in melanoma patients treated with immunotherapy or targeted therapy—A retrospective cohort study
por: Gatterbauer, Brigitte, et al.
Publicado: (2020)

Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta‐analysis of anti‐CTLA‐4 and anti‐PD‐1 agents trials
por: Yun, Seongseok, et al.
Publicado: (2016)

Integrative analysis of competing endogenous RNA network focusing on long noncoding RNA associated with progression of cutaneous melanoma
por: Xu, Siyi, et al.
Publicado: (2018)

Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR)
por: Sabol, Rachel A., et al.
Publicado: (2017)

Dual addressing of thymidine synthesis pathways for effective targeting of proliferating melanoma
por: Miran, Tara, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_lv91o3q742b2bpvmr4ke83csgg